Notably, DLBCL patients with high-risk scores exhibited lower proportions of CD8+ T cells, CD4+ memory activated T cells, gamma delta T cells, Macrophages M1, and resting mast cells, while showing elevated levels of native B cells and regulatory T (Treg) cells. Here, CD8A is linked to diffuse large B-cell lymphoma.